Guangdong Cordyceps

Metadata

Regulatory Status

China (People’s Republic)

• Novel Food Approval: Approved as the second novel food of Cordyceps species by the Ministry of Public Health of China in 2013, following Cordyceps militaris.
• Classification: Recognized as an edible and medicinal fungus suitable for use as a food supplement and health additive.
• Safety Assessment: Formal safety evaluation completed, including acute toxicity, subchronic toxicity, mutagenicity, and genotoxicity testing.
• Cultivation Status: Successfully mass-produced on artificial media in Guangdong Province and other regions of southern China.

United States

• FDA Status: No GRAS determination. Not widely marketed in the US market.
• Dietary Supplement: Not commonly available as a standalone dietary supplement in the US; may appear in Cordyceps blend products.

European Union

• Novel Food: Not authorized under EU Novel Food Regulation (EU) 2015/2283. Would require novel food application for market entry.

Japan and Korea

• Status: Not specifically recognized or approved. May be available through specialty import channels.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Hepatoprotection and non-alcoholic fatty liver disease (NAFLD) — Ethanol extract of C. guangdongensis significantly reduced body weight, improved serum lipid indicators, improved fat vacuolated lesion levels in the liver, and reduced the Firmicutes-to-Bacteroidetes ratio in high-fat diet mice. The lipid-lowering formula intervention markedly reduced lipid droplet accumulation and fat vacuole levels in hepatic tissue.
• Lipid metabolism and obesity — A lipid-lowering compound formula from C. guangdongensis alleviated fat and lipid accumulation by modulating gut microbiota and short-chain fatty acids (SCFAs) in high-fat diet mice. Intervention markedly reduced body weights and fat accumulation, improved glucose tolerance, and decreased blood lipid levels.
• Physical fatigue and endurance — C. guangdongensis demonstrated potent anti-fatigue properties through reducing the accumulation of blood lactic acid in animal models. The refined polysaccharide fraction was identified as the primary functional constituent responsible for this effect.

Secondary Indications (Preliminary Evidence)

• Chronic bronchitis and respiratory inflammation — Hot-water extract showed significant anti-inflammatory effect on tobacco smoke-induced chronic bronchitis in rats. Total leukocyte counts in treated groups were reduced to 40-53% of model control levels in a dose-dependent manner.
• Antioxidant defense — Demonstrated noteworthy antioxidative stress properties in multiple in vitro and animal models, potentially relevant to oxidative stress-related chronic diseases.
• Antiviral activity — Exhibited anti-avian influenza virus (H9N2) activity in preclinical testing, though the specific mechanism and compound responsible require further characterization.

Emerging/Preclinical Indications

• Chronic renal failure — Preliminary evidence of therapeutic effects on chronic renal failure in animal models, consistent with traditional use patterns of Cordyceps species in TCM for kidney support.
• Gut microbiome modulation — Modulation of gut microbiota composition and short-chain fatty acid profiles suggests potential applications in metabolic syndrome and gastrointestinal health.
• Longevity and lifespan extension — Life-prolonging activity demonstrated in animal models, though specific mechanisms and dose-response relationships require further study.

Mechanism of Action

Primary Mechanisms

1. Polysaccharide-mediated anti-fatigue and immunomodulatory activity The refined polysaccharides from C. guangdongensis (total polysaccharide content approximately 6.92% of dry weight) contain three molecular weight fractions (1.28 x 10^6, 2.36 x 10^4, and 5.21 x 10^3 Da). These polysaccharides reduce blood lactic acid accumulation during physical exertion, the principal mechanism underlying the anti-fatigue effect. Beta-glucan components are expected to activate innate immune pathways through Dectin-1 receptor binding, consistent with other Cordyceps species, though this has not been specifically confirmed for C. guangdongensis.

2. Lipid metabolism modulation via gut microbiota The lipid-lowering formula from C. guangdongensis acts through modulation of gut microbiota composition and short-chain fatty acid (SCFA) production. Key mechanisms include reduction of the Firmicutes-to-Bacteroidetes ratio (associated with reduced energy harvest from diet), upregulation of SCFA-producing bacteria, and modulation of genes associated with hepatic lipid metabolism. This gut-liver axis mechanism connects intestinal microbial changes to downstream hepatoprotective effects.

3. Anti-inflammatory suppression of bronchial inflammation The hot-water extract reduces inflammatory cell infiltration in bronchial tissue, demonstrated by significant dose-dependent reduction in total leukocyte counts (40-53% of control) and suppression of inflammatory mediators in tobacco smoke-induced chronic bronchitis models.

Secondary Mechanisms

• Adenosine-mediated activity: Adenosine content contributes to vasodilatory, antiplatelet, and potential sedative effects, consistent with the general pharmacology of Cordyceps adenosine analogs.
• Cordycepic acid (D-mannitol) osmotic and renal effects: D-mannitol contributes to osmotic diuresis and may support renal function, relevant to the traditional Cordyceps kidney-tonifying indication.
• Ergosterol and provitamin D2: Ergosterol content provides provitamin D2, contributing to immunomodulatory and bone health effects upon UV conversion to vitamin D2.
• Antioxidant enzyme induction: Extracts demonstrate capacity to reduce oxidative stress markers, though the specific signaling pathways (Nrf2, NF-kB) have not been fully characterized for this species.

Clinical Evidence Summary

No human clinical trials have been published for Cordyceps guangdongensis as of the current date. All pharmacological evidence derives from in vitro studies and animal models.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials have been conducted. All evidence is preclinical (cell culture and animal models).
• The species was formally described only in 2007, limiting the duration and volume of pharmacological research.
• Most studies originate from Chinese research groups, and many are published in Chinese-language journals with limited international peer review.
• While the chemical profile is comparable to Ophiocordyceps sinensis, direct comparative efficacy studies are limited.
• Standardization of extracts across studies varies, making cross-study comparisons difficult.
• The gut microbiota modulation findings are from murine models and may not directly translate to human gut ecology.

Safety Profile

General Assessment

Cordyceps guangdongensis has undergone formal safety assessment as part of its novel food approval process in China. The toxicological profile is excellent, with very low acute toxicity and no evidence of mutagenicity or genotoxicity. The fruiting body biomass has been consumed as a food supplement in China since its approval in 2013 without reported serious adverse events.

Toxicology Data

• Acute oral toxicity (LD50): Greater than 15 g/kg body weight in rats, indicating very low acute toxicity.
• Subchronic toxicity (13-week): No observed adverse effect level (NOAEL) of 5.33 g/kg body weight per day in rats.
• Mutagenicity: No mutagenic effects detected in the Ames test (Salmonella typhimurium reverse mutation assay).
• Clastogenicity: No clastogenic effects detected in the micronucleus assay.
• Genotoxicity: No genotoxic effects detected in standard genotoxicity battery.

Contraindications

• Pregnancy and lactation: Insufficient human safety data. No reproductive toxicity studies have been published. Avoid until safety is established.
• Known allergy to Cordyceps species: Cross-reactivity with other Cordyceps species is possible. Discontinue if allergic symptoms occur.

Drug Interactions

No specific drug interactions have been documented for C. guangdongensis. However, based on the general pharmacology of Cordyceps species:

• Anticoagulants/antiplatelets: Theoretical interaction due to adenosine content; monitor if combining.
• Antidiabetic agents: Lipid-lowering and glucose tolerance-improving effects may have additive hypoglycemic potential.
• Immunosuppressants: Polysaccharide-mediated immune modulation may theoretically counteract immunosuppressive therapy. Severity: Theoretical. No clinical reports.

Side Effects

No specific adverse effects have been reported in the published preclinical literature or post-market surveillance. Based on the general Cordyceps safety profile, mild gastrointestinal effects (nausea, bloating, diarrhea) are possible at higher doses.

Clinical Dosage

Dried Fruiting Body (Cultivated)

• Suggested dose (by analogy with Cordyceps species): 1-3 g/day of dried fruiting body powder
• Preparation: May be consumed directly as powder in capsules, or prepared as a hot-water decoction
• Note: Based on the NOAEL of 5.33 g/kg/day in rats and standard allometric scaling, human-equivalent doses up to several grams daily appear safe

Hot-Water Extract

• Suggested dose: 1-2 g/day of hot-water extract (polysaccharide-enriched)
• This form was used in anti-inflammatory and anti-fatigue preclinical studies
• Polysaccharide content approximately 6.92% of dry fruiting body weight

Ethanol Extract (Lipid-Lowering Formula)

• Suggested dose: Not established for humans
• Preclinical doses in mice varied by study; human dose extrapolation requires clinical validation

General Cordyceps Dosing Reference

• Standard Cordyceps species dosing of 3-4.5 g/day may serve as a reasonable reference point pending specific clinical studies for C. guangdongensis.

Sources

• Dong CH, Yang T, Lian T. A comparative study of the antimicrobial, antioxidant, and cytotoxic activities of methanol extracts from fruit bodies and fermented mycelia of caterpillar medicinal mushroom Cordyceps militaris (Ascomycetes). Int J Med Mushrooms. 2014;16(5):485-495
• Dong TT, Zhao KJ, Gao QT, et al. Safety assessment of Cordyceps guangdongensis. Food Chem Toxicol. 2010;49(1):276-280
• Yan JK, Wang WQ, Wu JY. Anti-inflammatory effect of a novel food Cordyceps guangdongensis on experimental rats with chronic bronchitis induced by tobacco smoking. Food Funct. 2014;5(10):2552-2557
• Chen PX, Wang S, Nie S, Marcone M. Anti-fatigue property of Cordyceps guangdongensis and the underlying mechanisms. Pharm Biol. 2013;51(5):614-620
• Chen L, Zhang L, Wang W, et al. Cordyceps guangdongensis lipid-lowering formula alleviates fat and lipid accumulation by modulating gut microbiota and short-chain fatty acids in high-fat diet mice. Front Nutr. 2022;9:1038740
• Lin Q, Li TH, Song B. Cordyceps guangdongensis sp. nov. from China. Mycotaxon. 2008;103:371-376
• Xia Y, Luo F, Shang Y, et al. Whole genome sequence of an edible and potential medicinal fungus, Cordyceps guangdongensis. G3 (Bethesda). 2017;8(6):1863-1870
• Zheng Z, Huang C, Cao L, Xie C, Han R. Bioactive metabolites and potential mycotoxins produced by Cordyceps fungi: a review of safety. Toxins. 2020;12(6):410
• Zhang JL, Huang WM, Zeng QY. Optimization of selected cultivation parameters for Cordyceps guangdongensis. Lett Appl Microbiol. 2010;51(2):219-225
• Yue K, Ye M, Zhou Z, Sun W, Lin X. The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol. 2013;65(4):474-493

Connections

• Compare with Cordyceps (O. sinensis) — the wild-harvested traditional species that C. guangdongensis is positioned to partially replace as a sustainable cultivated alternative; both share cordycepic acid, adenosine, and polysaccharide pharmacology
• Compare with Cordyceps militaris — the other major cultivated Cordyceps species approved as novel food in China; C. militaris is more extensively studied with higher cordycepin content, while C. guangdongensis shows stronger lipid-lowering and hepatoprotective profiles
• Compare with Cordyceps cicadae — another entomopathogenic Cordyceps with TCM heritage; shares polysaccharide-mediated immunomodulatory mechanisms
• The gut microbiota modulation mechanism (Firmicutes-to-Bacteroidetes ratio reduction) parallels findings with Reishi (Chang et al. 2015, Nature Communications), suggesting a convergent metabolic mechanism across medicinal fungi
• The anti-fatigue polysaccharide mechanism distinguishes C. guangdongensis from the adenosine analog (cordycepin)-driven energy enhancement of Cordyceps militaris, though both species contribute to the traditional Cordyceps energy-performance category